30.91 USD
-0.3 (-0.96%)
30.91 USD
0 (0%)
Taking everything into account, STOK scores 5 out of 10 in our fundamental rating. STOK was compared to 533 industry peers in the Biotechnology industry. While STOK has a great health rating, its profitability is only average at the moment. STOK is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year STOK was profitable.
In the past year STOK had a positive cash flow from operations.
STOK had negative earnings in each of the past 5 years.
STOK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
STOK has a better Return On Assets (11.39%) than 94.18% of its industry peers.
STOK has a better Return On Equity (13.32%) than 94.37% of its industry peers.
STOK's Return On Invested Capital of 6.66% is amongst the best of the industry. STOK outperforms 93.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.39% | ||
| ROE | 13.32% | ||
| ROIC | 6.66% |
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 19.96%, STOK belongs to the top of the industry, outperforming 94.18% of the companies in the same industry.
STOK has a Operating Margin of 13.06%. This is amongst the best in the industry. STOK outperforms 92.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.06% | ||
| PM (TTM) | 19.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), STOK is destroying value.
The number of shares outstanding for STOK has been increased compared to 1 year ago.
Compared to 5 years ago, STOK has more shares outstanding
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 20.38 indicates that STOK is not in any danger for bankruptcy at the moment.
The Altman-Z score of STOK (20.38) is better than 89.87% of its industry peers.
STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.38 |
ROIC/WACC0.77
WACC8.64%
2.3 Liquidity
STOK has a Current Ratio of 6.53. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.53, STOK is doing good in the industry, outperforming 67.92% of the companies in the same industry.
A Quick Ratio of 6.53 indicates that STOK has no problem at all paying its short term obligations.
STOK has a Quick ratio of 6.53. This is in the better half of the industry: STOK outperforms 68.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.53 | ||
| Quick Ratio | 6.53 |
3. Growth
3.1 Past
STOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 135.71%, which is quite impressive.
STOK shows a strong growth in Revenue. In the last year, the Revenue has grown by 1128.17%.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.3%
Revenue 1Y (TTM)1128.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%117.25%
3.2 Future
Based on estimates for the next years, STOK will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.62% on average per year.
Based on estimates for the next years, STOK will show a very strong growth in Revenue. The Revenue will grow by 69.74% on average per year.
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
EPS Next 5Y14.62%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y69.74%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 41.21, STOK can be considered very expensive at the moment.
90.81% of the companies in the same industry are more expensive than STOK, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.15, STOK is valued quite expensively.
The Forward Price/Earnings Ratio is negative for STOK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.21 | ||
| Fwd PE | N/A |
4.2 Price Multiples
STOK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. STOK is cheaper than 90.62% of the companies in the same industry.
93.06% of the companies in the same industry are more expensive than STOK, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.59 | ||
| EV/EBITDA | 47.64 |
4.3 Compensation for Growth
STOK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as STOK's earnings are expected to decrease with -16.29% in the coming years.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
5. Dividend
5.1 Amount
No dividends for STOK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
30.91
-0.3 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners118.79%
Inst Owner Change-2.02%
Ins Owners4.3%
Ins Owner Change-34.51%
Market Cap1.77B
Revenue(TTM)205.63M
Net Income(TTM)41.05M
Analysts84.71
Price Target31.51 (1.94%)
Short Float %20.36%
Short Ratio8.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.64%
Min EPS beat(2)-12.12%
Max EPS beat(2)23.41%
EPS beat(4)3
Avg EPS beat(4)159.13%
Min EPS beat(4)-12.12%
Max EPS beat(4)558.67%
EPS beat(8)7
Avg EPS beat(8)85.57%
EPS beat(12)10
Avg EPS beat(12)60.58%
EPS beat(16)12
Avg EPS beat(16)28.75%
Revenue beat(2)2
Avg Revenue beat(2)60.62%
Min Revenue beat(2)52.02%
Max Revenue beat(2)69.22%
Revenue beat(4)4
Avg Revenue beat(4)553.32%
Min Revenue beat(4)52.02%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)289.38%
Revenue beat(12)10
Avg Revenue beat(12)187.93%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)27.52%
PT rev (3m)33.01%
EPS NQ rev (1m)-16.37%
EPS NQ rev (3m)-16%
EPS NY rev (1m)0%
EPS NY rev (3m)384.17%
Revenue NQ rev (1m)20.13%
Revenue NQ rev (3m)1.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.21 | ||
| Fwd PE | N/A | ||
| P/S | 8.59 | ||
| P/FCF | 33.59 | ||
| P/OCF | 33.29 | ||
| P/B | 5.73 | ||
| P/tB | 5.73 | ||
| EV/EBITDA | 47.64 |
EPS(TTM)0.75
EY2.43%
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)0.92
FCFY2.98%
OCF(TTM)0.93
OCFY3%
SpS3.6
BVpS5.39
TBVpS5.39
PEG (NY)0.35
PEG (5Y)N/A
Graham Number9.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.39% | ||
| ROE | 13.32% | ||
| ROCE | 8.43% | ||
| ROIC | 6.66% | ||
| ROICexc | 30.2% | ||
| ROICexgc | 30.2% | ||
| OM | 13.06% | ||
| PM (TTM) | 19.96% | ||
| GM | N/A | ||
| FCFM | 25.56% |
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 25.22% | ||
| Cap/Sales | 0.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 184.52% | ||
| Profit Quality | 128.04% | ||
| Current Ratio | 6.53 | ||
| Quick Ratio | 6.53 | ||
| Altman-Z | 20.38 |
F-Score8
WACC8.64%
ROIC/WACC0.77
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.3%
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.29%
EPS Next 5Y14.62%
Revenue 1Y (TTM)1128.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%117.25%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y69.74%
EBIT growth 1Y122.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.74%
EBIT Next 3Y-11.06%
EBIT Next 5Y23.88%
FCF growth 1Y162.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y164.06%
OCF growth 3YN/A
OCF growth 5YN/A
STOKE THERAPEUTICS INC / STOK FAQ
What is the fundamental rating for STOK stock?
ChartMill assigns a fundamental rating of 5 / 10 to STOK.
What is the valuation status for STOK stock?
ChartMill assigns a valuation rating of 4 / 10 to STOKE THERAPEUTICS INC (STOK). This can be considered as Fairly Valued.
Can you provide the profitability details for STOKE THERAPEUTICS INC?
STOKE THERAPEUTICS INC (STOK) has a profitability rating of 4 / 10.
What is the valuation of STOKE THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for STOKE THERAPEUTICS INC (STOK) is 41.21 and the Price/Book (PB) ratio is 5.73.